AllDocs -> cancers

A204: Liver cancer tissues - Hepatocellular carcinoma For research use only (formalin fixed) Specifications: •No. of cases: 35 •Tissue type: Liver cancer tissues – Hepatocellular carcinoma •No. of spots: 2 spots from each cancer case (70 spots) 4 non-neoplastic spots (4 spots) •Total spots: 74 •Corresponding normal tissues with cancers: Yes •Diameter: 1.0 mm Documents: •Product specification: layout, summary of tissue spots •H&E stained images •Detailed pathological information Layout: Page 2 A204 : Liver cancer tissues - Hepatocellular carcinoma For research use only (formalin fixed) Summary of tissue spots No. Sex Age Key Word E-S grade* TNM Stage 1 1, 2 f 48 hepatocellular carcinoma I T2NxM0 ...

del file contenuto in http://www.arccnm.org/what_new/download/Abstract_Radiolabelled_antibody_therapy_for_Lymphoma_Dr_Sundram.rtf . G o o g l e crea automaticamente la versione .html dei documenti durante la scansione del Web. Per inserire un segnalibro o un collegamento alla pagina, utilizzare il seguente URL: http://www.google.com/search?q=cache:dyORar4rEagJ:www.arccnm.org/what_new/download/Abstract_Radiolabelled_antibody_therapy_for_Lymphoma_Dr_Sundram.rtf+allintitle:+liver+cancer+filetype:pdf+OR++filetype:doc+OR+filetype:ppt+OR++filetype:xls+OR+filetype:rtf&hl=it&lr=lang_en Google non ?ollegato agli autori di questa pagina e non ?esponsabile del suo contenuto. I termini specificati sono presenti solamente in collegamenti che rimandano alla seguente pagina: allintitle liver cancer Radiolabelled antibody therapy for Lymphoma Felix Sundram, Head, Department of Nuclear Medicine and PET, Singapore General Hospital ...

The Gambia Liver Cancer Study: Infection With Hepatitis B and C and the Risk of Hepatocellular Carcinoma in West Africa Gregory D. Kirk, 1,2 Olufunmilayo A. Lesi, 2,7 Maimuna Mendy, 4 Aliu O. Akano, 5,7 Omar Sam, 5 James J. Goedert, 1 Pierre Hainaut, 3 Andrew J. Hall, 6 Hilton Whittle, 4 and Ruggero Montesano 3 Hepatocellular carcinoma (HCC) is the most common cancer in The Gambia. Hepatitis B virus (HBV) infection is endemic, with 15% to 20% of the population being chronic carriers, whereas hepatitis C virus (HCV) prevalence is low. We recruited 216 incident cases of HCC and 408 controls from three sites. HBV carriage was present in 61% (129/211) of HCC patients and 16% (64/402) of controls, whereas 19% (36/191) of HCC patients were HCV ...

: liver cancer TESTIMONIAL: LIVER CANCER STAGE IV Patient: Clifford Bouma Da te of Treatment: Jan 2000 Da te of Testimonial: Sept 2001 Diagnosis Date: Fall 1999 I was told by my doctor that patients with liver cancer survive an average of eight months. In Jan uary of 2000, I received my first treatment for liver cancer in a clinic dedicated to the use of non-toxic therapies. I received Lymphocyte Activated Killer Cells and Dendritic Cell Therapy. It is now September 2001 (One year and nine months later) and I still have my challenges, yet the clinic continues to use the best strategies to help me live. I owe my extended life to God and know God has given a special call to the staff of this clinic to help bring healing to Creation. Clifford Bouma

liver cancer TESTIMONIAL: LIVER CANCER STAGE IV Patient: Robert Graham Date of Treatment: May, 2001 Date of Testimonial: May 13, 2003 In April 2001, my surgeon told me if I discontinued chemotherapy I?d be lucky to live for three months. I was diagnosed with colorectal cancer and liver metastasis. When my physician wanted to move to a stronger chemotherapy, I make my decision to pursue immunotherapy. This included autologous Dendritic Cells and autologous Total Killer Cell Therapy. After one month, I felt I looked better that I ever had, even before my original diagnosis. No one could believe that I had Stage IV cancer . Now I still run a business and play golf 2-3 days a week. I tell everyone who comments on my health that I saw a miracle a day during this treatment. I feel blessed to have had this ...

Last revised: 4/20/04 UM Cancer Center Patient Education Document #0032 Apr04 Ed. Online version: http://www. cancer .med.umich.edu/learn/percpathways.htm University of Michigan Comprehensive Cancer Center Patient Education Resource Center (PERC) INFORMATION GUIDE Liver Cancer The purpose of this information guide is to help patients newly diagnosed with Liver Cancer and their families to find sources of information and support. This list is not meant to be comprehensive, but rather to provide starting points for information seeking. The materials can be found at the Patient Education Resource Center at the University of Michigan Comprehensive Cancer Center in room B1-361. Brochure Available free at the Patient Education Resource Center on Level B-1 National Cancer Institute. What You Need To Know About: ...

RISK FACTOR INFORMATION FOR SELECTED CANCER TYPES Source: Community Assessment Unit, Bureau of Environmental Health Assessment, Massachusetts Department of Public Health December, 2002 Liver Cancer An estimated 16,600 people in the U.S. (11,000 men and 5,600 women) will be diagnosed with liver cancer in 2002, accounting for approximately 1% of all new cancers (ACS, 2002). Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver , accounting for about 75% of all cases. Rarer forms of malignant liver cancer include cholangiocarcinomas, angiosarcomas, and hepatoblastomas in children. Although HCC is approximately ten times more common in developing countries in East and Southeast Asia and Africa, incidence is rapidly increasing in the United States (ACS, 2001). Rates of HCC in the U.S. have increased by 70% over the past two decades (Yu et al., ...

RISK FACTOR INFORMATION FOR SELECTED CANCER TYPES Source: Community Assessment Unit, Bureau of Environmental Health Assessment, Massachusetts Department of Public Health August, 2001 Liver Cancer An estimated 16,200 people in the U.S. (10,700 men and 5,500 women) will be diagnosed with liver cancer in 2001, accounting for approximately 1% of all new cancers (ACS, 2001a). Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver , accounting for about 75% of all cases. Rarer forms of malignant liver cancer include cholangiocarcinomas, angiosarcomas, and hepatoblastomas in children. Although HCC is approximately ten times more common in developing countries in East and Southeast Asia and Africa, incidence is rapidly increasing in the United States (ACS, 2001b). Rates of HCC in the U.S. have increased by 70% over the past two decades (Yu et al., 2000). ...

FINAL REPORT U.S. Department of Energy MECHANISMS INVOLVED IN TRICHLOROETHYLENE INDUCED LIVER CANCER : IMPORTANCE TO ENVIRONMENTAL CLEANUP Principal Investigator: Richard J. Bull Co-Investigator: Brian D. Thrall Pacific Northwest National Laboratory Collaborators: Lyle B. Sasser, John H. Miller, Irvin R. Schultz Pacific Northwest National Laboratory Project Number: 54684 Project Duration: 9/15/96 – 3/15/01 DOE Contract Number: DE-ACO6-76RLO 1830 Page 2 2 Contents Executive Summary.4 1.0 Research Objectives . 6 2.0 Methods and Results. 8 2.1 Summary of Pharmacokinetic Findings 8 2.2 Summary of In vitro Findings 9 2.3 Description of Chronic Tumor Studies .. 10 2.3.1 Experimental Animals .. 10 2.3.2 Tumor Sampling, PCR Amplification, and Sequencing . 11 2.3.3 Analysis 12 ...

Last Revised: 3/8/2004 UM Comprehensive Cancer Center Patient Education Document # 0015 Mar04 Ed. Online version: http://www. cancer .med.umich.edu/learn/percpathways.htm University of Michigan Comprehensive Cancer Center Patient Education Resource Center (PERC) INFORMATION GUIDE Childhood Cancer : Liver Cancers The purpose of this information guide is to help parents of children newly diagnosed with liver tumors find sources of information and support. This list is not meant to be comprehensive, but rather to provide starting points for information seeking. The materials can be found at the Patient Education Resource Center at the University of Michigan Comprehensive Cancer Center in room B1-361. Book Chapters Available for loan in the Patient Education Resource Center on level B1 room 361 Janes-Hodder, ...

127 MEDICINA (2004) 40 tomas, Nr. 2 KLINIKINIAI TYRIMAI Results of treatment of primary liver cancer at Kaunas University of Medicine Hospital Mindaugas Jievaltas, Laura Stoškuviene 1 , Vitalija Petrenkiene 2 , Giedrius Barauskas, Juozas Pundzius Clinic of Surgery, Kaunas University of Medicine Hospital, 1 Faculty of Medicine, Kaunas University of Medicine, 2 Clinic of Gastroenterology, Kaunas University of Medicine Hospital, Lithuania Key words: hepatocellular carcinoma, liver resection. Summary. Though the results of treatment of primary liver cancer depend on many circumstances, the opportunity to perform a curative liver resection remains the main point in prognosis on survival. The aim of the study was to examine our first experience in the treatment of liver ...

Genetic Profiling of Colorectal Cancer Liver Metastases by Combined Comparative Genomic Hybridization and G-Banding Analysis Chieu B. Diep, 1 Luis A. Parada, 2 Manuel R. Teixeira, 3 Mette Eknæs, 1 Jahn M. Nesland, 4 Bertil Johansson, 2 and Ragnhild A. Lothe 1 * 1 Department of Genetics, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway 2 Department of Clinical Genetics, Lund University Hospital, Lund, Sweden 3 Department of Genetics, Portuguese Oncology Institute, Porto, Portugal 4 Department of Pathology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway The majority of genetic studies of colorectal carcinogenesis have focused on changes found in primary tumors. Despite ...

74 A SYSTEM FOR THE TREATMENT OF LIVER CANCER BY TARGETED HYPERTHERMIA USING MAGNETIC MICROSPHERES S. K. Jones 1 P. Moroz 2 and B. N. Gray 1 1 Sirtex Medical Ltd, North Ryde, NSW 1670, Australia, 2 University of Western Australia, Crawley, WA 6009, Australia ABSTRACT: Sirtex Medical Limited is developing new technology to treat liver cancer by induced hyperthermia using magnetic microspheres. Eighty to ninety percent of patients presenting with primary or secondary liver cancer have inoperable disease and a poor prognosis [1-4]. The median survival for patients with non-resectable hepatocellular carcinoma is three to six months [5,6], and six to 12 months for patients with non-resectable hepatic colorectal metastases [7]. These patients must rely largely on various forms ...

Q and A: Glutamine, Liver Cancer and Apoptosis Background As you should have learned in BL A302 and 304, amino acids serve several roles in cellular metabolism. They act as precursors in protein synthesis, nitrogen donors in some biosynthetic pathways (nucleotides, amino sugars, amino acids, urea) and carbon donors in other biosynthetic pathways (gluconeogenesis, nucleotides, lipids). Their carbon skeletons can be used as oxidizable substrates (TCA cycle (ATP synthesis)) and they can be utilized in the biosynthesis of polyamines and glutathione. This semester you will learn that they are important for hormone synthesis (thyroid hormones (T 4 and T 3 ), epinephrine) and neurotransmitter biosynthesis (GABA, acetylcholine, serotonin, catecholamines, dopamine, norepinephrine, epinephrine)), and can even act as neurotransmitters (glutamate, glycine). Amino acid metabolism ...

Cancer of the Liver Liver cancer can be due to malignant changes in the liver cells themselves—called primary liver cancer —or it can be due to a cancer spreading from another site to the liver —called secondary liver cancer . This message focuses on primary liver cancer , and does not address secondary liver cancer . Cancer that has spread to the liver from another site retains the characteristics and behavior of the original tumor—whether it is breast, colon, pancreatic, stomach, or some other cancer . In North and South America and in Europe, primary liver cancers account for only one to two percent of malignant tumors. However, in parts of Africa and Asia, they are much more common, accounting for 20 to 30 percent of malignancies. Liver cancer is four times as common in men as in women. In Western countries, it occurs most commonly in people ...

Center for Environmental Health Studies (617) 482-9485 44 Farnsworth Street, Boston, MA 02210 http://www.jsi.com Liver Cancer and Exposure to Ionizing Radiation 1 Liver Cancer and (including intra-hepatic bile duct) Exposure to Ionizing Radiation Summary: Moderately strong evidence has been recorded of a possible connection between liver cancer deaths and exposure to ionizing radiation. This evidence is based upon studies conducted at Los Alamos National Laboratory, studies of nuclear workers at other sites, and others exposed to ionizing radiation. These findings are consistent with the National Research Council’s determination that the liver is sensitive to ionizing radiation. Liver cancer is designated as a “specified” cancer under the Energy Employees Occupational Illness Compensation Program Act. Historically, incidence of ...

liver cancer Liver Cancer A leading cause of death in the world Can be primary or a metastatic site Seen more in other parts of the world incidence African American males 40 – 60 years old Cirrhosis Hepatitis B and C Causes of Liver Cancer Primary Trauma Nutritional deficits ...

P.O.Box 2345, Beijing 100023,China World J Gastroenterol 2003;9(2):193-200 Fax: +86-10-85381893 World Journal of Gastroenterology E-mail: wjg@wjgnet.com www.wjgnet.com Copyright © 2003 by The WJG Press ISSN 1007-9327 • REVIEW • Current treatment for liver metastases from colorectal cancer Lian-Xin Liu, Wei-Hui Zhang, Hong-Chi Jiang Lian-Xin Liu, Wei-Hui Zhang, Hong-Chi Jiang, Department of Surgery, the First Clinical College, Harbin Medical University, Harbin 150001, Heilongjiang Province, China Supported by Youth Natural Science Foundation of Heilongjiang Province Correspondence to: Dr Lian-Xin Liu, Department of Surgery, First Clinical College, Harbin Medical University, No. 23 Youzheng Street, Nangang District, Harbin 150001, Heilongjiang Province, China. liulianxin@sohu.com Telephone: +86-451-3643849-5885 Fax: +86-451-3670428 Received: ...

504 JMAJ, November 2003—Vol. 46, No. 11 Need to Control Hepatitis, a Very Common Disease in Japan Following the discovery of hepatitis B virus in 1964, hepatitis viruses A and C were identi- fied in 1972 and 1989, respectively. The roles of these viruses in Japan have been increasingly well clarified. That is, the pathophysiology of the three types of viral hepatitis has been eluci- dated, and appropriate treatment measures have been established. In the past, it was a clinical practice at out- patient liver clinics in Japan to inform patients of changes in their serum GOT and GPT levels. Prediction, Prevention and Treatment of Liver Cancer JMAJ 46(11): 504–511, 2003 Masao OMATA Professor, Department of Gastroenterology, Graduate School of Medicine, University of Tokyo Abstract: Hepatitis virus infection has ...

Web Immagini Gruppi Directory News Novità! Ricerca avanzata Preferenze Cerca nel Web Cerca solo le pagine in Inglese Spiacenti, nessun contenuto associato a questo URL Web La ricerca di - cache:mELkIjRWOLQJ:www.janani.org/protopdf/fp/5-7.pdf allintitle: liver cancer filetype:pdf OR filetype:doc OR filetype:ppt OR filetype:xls OR filetype:rtf - non ha prodotto risultati in nessun documento. Suggerimenti: - Assicurarsi che tutte le parole siano state digitate correttamente. - Provare con parole chiave diverse. - Provare con parole chiave più generiche. - Provare con un numero minore di parole chiave. ...

Liver cancer -results Liver cancer -results John Buscombe John Buscombe Page 2 Methods of treatment Methods of treatment Directed to HCC Directed to HCC Vascular tumours Vascular tumours Supplied by Hep artery Supplied by Hep artery (normal liver also Portal vein) (normal liver also Portal vein) Ability to deliver radioactivity by catheter Ability to deliver radioactivity by catheter 2 main methods 2 main methods Y-90 labelled Y-90 labelled microspheres microspheres Labelled Labelled Lipiodol/Chitosan Lipiodol/Chitosan Page 3 SIR spheres SIR spheres They are tiny glass beads They are tiny glass beads 35 micron in size 35 micron in size ...

Sirtex Medical – A Proven Liver Cancer Treatment 16 July 2003 Code SRX Market Cap $240M Shares on Issue 55M Last $4.35 Overview Specialist in liver cancer treatment products, SIR-Sphere Technology Expecting maiden profit this year (ended 30/6) of $1.5m, $10m cash in bank, no debt. 53 hospitals can now deliver the SIR-Spheres treatment process including 18 in the USA, 4 in Europe, 20 in Australia and the balance in Asia and NZ. Main competitor in the US recently failed to gain FDA approval. Takeover bid by US company Cephalon at $4.85 per share failed, we do not rule out corporate activity in the future Background Sirtex Medical Limited (SRX) was formed in 1997 to acquire and commercialise treatments for liver cancers developed by Dr Bruce Gray and the Cancer Research Institute (CRI). Sirtex’s primary focus is on SIR-Spheres (Selective Internal Radiation) ...

Web Immagini Gruppi Directory News Ricerca avanzata Preferenze Cerca nel Web Cerca solo le pagine in Inglese Spiacenti, nessun contenuto associato a questo URL Web La ricerca di - cache:COMNwDK4iYgJ:www.wjgnet.com/1009-3079/11/908.pdf allintitle: liver cancer filetype:pdf OR filetype:doc OR filetype:ppt OR filetype:xls OR filetype:rtf - non ha prodotto risultati in nessun documento. Suggerimenti: - Assicurarsi che tutte le parole siano state digitate correttamente. - Provare con parole chiave diverse. - Provare con parole chiave più generiche. - Provare con un numero minore di parole chiave. ©2004 Google ...

Regional chemotherapy of non-resectable liver metastases from colorectal cancer - literature and institutional review. Link KH, Kornmann M, Formentini A, Leder G, Sunelaitis E, Schatz M, Pressmar J, Beger HG. Department of General Surgery, University Hospital of Ulm, Steinhoevelstr. 9, 89075 Ulm, Germany. BACKGROUND: Cure is possible by resecting colorectal isolated liver metastases. In non-resectable isolated colorectal liver metastases (CRLM), regional chemotherapy has been advocated to optimize the disease control in the liver in order to improve the results of the alternative, systemic chemotherapy. The drugs are delivered by means of hepatic artery infusion (HAI) via ports or pumps; pharmacological modifications of the hepatic arterial blood-flow-like HAI with starch microspheres or stop-flow and perfusion techniques were applied to improve HAI. METHODS: We reviewed the ...

liver cancer Prevention of Liver Cancer THOMAS W. KENSLER Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205 Hepatocarcinogenesis (HCC) is the fifth leading cause of cancer mortality in the world, and in parts of Asia and Africa it accounts for nearly 70% of cancer deaths . The 5-year mortality rate for individuals diagnosed with HCC is greater than 95%. In the People's Republic of China, HCC accounts for at least 250,000 deaths per year, particularly among men, with an incidence rate in some counties approaching 100 cases per 100,000 per year. Moreover, in high-risk regions of the world the median age of onset of HCC is decades earlier than in the U.S. The geographic distribution of HCC cases indicates some risk factors that could cause a predisposition to this disease. In particular, areas where viral hepatitis infection is endemic also show high incidence ...

The 1996-2000 average annual age-adjusted incidence rate for invasive cancers of the liver and intrahepatic bile duct was almost three times higher in males than in females (6.8 compared to 2.4 per 100,000), and blacks of both sexes had higher rates compared to whites. There were 708 cases of liver /intrahepatic bile duct cancers diagnosed and reported among residents of Pennsylvania for 2000 – the highest annual figure recorded between 1991 and 2000. The annual age-adjusted incidence rates by sex and race for ten years (1991 through 2000) showed increasing rates among males, especially black males, and females of both races. The 1996-2000 average annual age-specific incidence rates show that black males have had the highest risks. During the period of 1996-2000, over 62 percent of the cases were diagnosed among residents 65 years of age or older. In 2000, over 57 percent of the staged liver /intrahepatic bile duct cancers were ...

P.O.Box 2345, Beijing 100023,China World J Gastroenterol 2003;9(7):1618-1620 Fax: +86-10-85381893 World Journal of Gastroenterology E-mail: wjg@wjgnet.com www.wjgnet.com Copyright © 2003 by The WJG Press ISSN 1007-9327 • BRIEF REPORTS • Fatty metamorphosis of the liver in patients with breast cancer : Possible associated factors Cheng-Hsin Chu, Shee-Chan Lin, Shou-Chuan Shih, Chin-Roa Kao, Sun-Yen Chou Cheng-Hsin Chu, Shee-Chan Lin, Shou-Chuan Shih, Chin-Roa Kao, Sun-Yen Chou , Division of Gastroenterology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan, China Correspondence to: Dr. Cheng-Hsin Chu, Department of Hepatology and Gastroenterology, Mackay Memorial Hospital, Address: No. 92, Sec. 2, Chung-Shan N. Road, Taipei, Taiwan, China. suyu5288@ms14.hinet.net Telephone: +86-2-88661107 Fax: +86-2-25433642 Received: 2003-02-25 ...